Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

Medpace Holdings IncTrade
Virgin Galactic Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while Virgin Galactic Holdings, Inc. trades at $2.73 (market cap $329.06M). The key difference: Medpace Holdings Inc is far larger — about 45.8× Virgin Galactic Holdings, Inc.'s market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.

MEDPSPCE
Market Cap
$15.08B$329.06M
Sector
TechnologyIndustrials
52-Week High
$620.59$7.52
52-Week Low
$308.88$2.17
Enterprise Value
$14.55B$428.90M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.

The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.

Virgin Galactic Holdings, Inc.

SPCE trades at $2.78, up 8.59% in the last session, but remains in a bearish technical trend with negative cash flows and deep losses. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with profitability metrics deeply negative. Recent news highlights volatility tied to space sector sentiment and SpaceX's market activities, contributing to sharp price swings.

The outlook is highly speculative with significant execution and funding risks. While analyst ratings are mixed, the lack of revenue scale and persistent cash burn pose substantial challenges. Investment potential hinges on successful commercialization, but current fundamentals do not support a sustainable valuation, making it suitable only for high-risk investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Virgin Galactic Holdings, Inc.

Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.

Read more on SPCE